[ad_1]
Artemis Investment Management LLP bought a new stake in shares of Johnson & Johnson (NYSE:JNJ) during the third quarter, according to the company in its most recent filing with the SEC. The institutional investor bought 88,295 shares of the company’s stock, valued at approximately $11,478,000.
A number of other large investors also recently made changes to their positions in the business. Vanguard Group Inc. raised its position in shares of Johnson & Johnson by 1.5% in the 2nd quarter. Vanguard Group Inc. now owns 200,450,985 shares of the company’s stock worth $26,517,661,000 after buying an additional 3,023,110 shares during the period. BlackRock Inc. raised its position in shares of Johnson & Johnson by 2.6% in the 2nd quarter. BlackRock Inc. now owns 174,073,764 shares of the company’s stock worth $23,028,219,000 after buying an additional 4,332,612 shares during the period. FMR LLC raised its position in shares of Johnson & Johnson by 5.9% in the 2nd quarter. FMR LLC now owns 27,237,648 shares of the company’s stock worth $3,603,268,000 after buying an additional 1,509,745 shares during the period. Capital World Investors raised its position in shares of Johnson & Johnson by 4.1% in the 2nd quarter. Capital World Investors now owns 26,510,007 shares of the company’s stock worth $3,507,009,000 after buying an additional 1,050,000 shares during the period. Finally, Ameriprise Financial Inc. raised its position in shares of Johnson & Johnson by 4.5% in the 2nd quarter. Ameriprise Financial Inc. now owns 17,860,047 shares of the company’s stock worth $2,363,788,000 after buying an additional 771,039 shares during the period. Hedge funds and other institutional investors own 65.72% of the company’s stock.
Several research analysts have commented on the company. Stifel Nicolaus raised their price objective on Johnson & Johnson from $142.00 to $145.00 and gave the company a “hold” rating in a research report on Wednesday. BTIG Research reissued a “sell” rating and issued a $110.00 price objective on shares of Johnson & Johnson in a research report on Wednesday. Vetr raised Johnson & Johnson from a “hold” rating to a “buy” rating and set a $152.28 price objective on the stock in a research report on Tuesday, January 23rd. Credit Suisse Group set a $154.00 price objective on Johnson & Johnson and gave the company a “hold” rating in a research report on Monday, January 22nd. Finally, Wells Fargo & Co reissued an “outperform” rating and issued a $160.00 price objective (up from $155.00) on shares of Johnson & Johnson in a research report on Friday, January 12th. Four analysts have rated the stock with a sell rating, eight have given a hold rating and ten have given a buy rating to the company. The stock presently has an average rating of “Hold” and an average price target of $146.16.
Shares of Johnson & Johnson (NYSE:JNJ) traded up $0.93 during trading on Friday, hitting $145.33. The stock had a trading volume of 6,979,094 shares, compared to its average volume of 6,970,000. The firm has a market capitalization of $390,430.00, a P/E ratio of 372.64, a PEG ratio of 2.59 and a beta of 0.80. Johnson & Johnson has a 12 month low of $111.90 and a 12 month high of $148.32. The company has a quick ratio of 1.02, a current ratio of 1.32 and a debt-to-equity ratio of 0.36.
Johnson & Johnson (NYSE:JNJ) last posted its quarterly earnings results on Tuesday, January 23rd. The company reported $1.74 EPS for the quarter, topping the Zacks’ consensus estimate of $1.72 by $0.02. The business had revenue of $20.20 billion during the quarter, compared to the consensus estimate of $20.08 billion. Johnson & Johnson had a return on equity of 27.80% and a net margin of 1.70%. The company’s revenue for the quarter was up 11.5% compared to the same quarter last year. During the same period last year, the firm earned $1.58 earnings per share. sell-side analysts expect that Johnson & Johnson will post 8.1 earnings per share for the current year.
The company also recently declared a quarterly dividend, which will be paid on Tuesday, March 13th. Investors of record on Tuesday, February 27th will be paid a $0.84 dividend. The ex-dividend date is Monday, February 26th. This represents a $3.36 dividend on an annualized basis and a yield of 2.31%. Johnson & Johnson’s dividend payout ratio (DPR) is 861.54%.
COPYRIGHT VIOLATION NOTICE: “Artemis Investment Management LLP Buys Shares of 88,295 Johnson & Johnson (NYSE:JNJ)” was first posted by Week Herald and is owned by of Week Herald. If you are accessing this news story on another website, it was illegally copied and republished in violation of US and international copyright legislation. The correct version of this news story can be viewed at https://weekherald.com/2018/01/28/artemis-investment-management-llp-buys-new-position-in-johnson-johnson-jnj.html.
About Johnson & Johnson
Johnson & Johnson is a holding company, which is engaged in the research and development, manufacture and sale of a range of products in the healthcare field. It operates through three segments: Consumer, Pharmaceutical and Medical Devices. Its primary focus is products related to human health and well-being.
Receive News & Ratings for Johnson & Johnson Daily – Enter your email address below to receive a concise daily summary of the latest news and analysts’ ratings for Johnson & Johnson and related companies with MarketBeat.com’s FREE daily email newsletter.
[ad_2]
Source link
